nach oben

Translational Stroke Research

Erschienen in:

07.01.2016 | SI: Challenges and Controversies in Translational Stroke Research

Extending the Time Window for Endovascular and Pharmacological Reperfusion

verfasst von: Nils Henninger, Marc Fisher

Erschienen in: Translational Stroke Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Pharmacological and device-induced reperfusion therapies have demonstrated increasingly positive outcomes regarding both reperfusion efficacy and 90-day functional outcomes after acute ischemic stroke. However, presently, only a minority of patients are eligible for these treatments. Less than 10 % of all ischemic stroke patients receive intravenous thrombolysis in most centers and it has been projected that only approximately 7–15 % of ischemic stroke patients are eligible for acute endovascular intervention. Making these effective therapies safely available to a much larger number of patients is critical for expanding the benefits of acute ischemic stroke treatment. In this article, we summarize the key results from the clinical trials, challenges, and exciting novel opportunities to increase patient eligibility for these therapies as well as for better outcomes for stroke patients.

Puyal J, Ginet V, Clarke PG. Multiple interacting cell death mechanisms in the mediation of excitotoxicity and ischemic brain damage: a challenge for neuroprotection. Prog Neurobiol. 2013;105:24–48. doi:10.1016/j.pneurobio.2013.03.002.CrossRefPubMed

Schabitz WR, Fisher M. Perspectives on neuroprotective stroke therapy. Biochem Soc Trans. 2006;34:1271–6. doi:10.1042/BST0341271.CrossRefPubMed

Henninger N, Kumar R, Fisher M. Acute ischemic stroke therapy. Expert Rev Cardiovasc Ther. 2010;8:1389–98. doi:10.1586/erc.10.128.CrossRefPubMed

Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol. 2007;61:396–402. doi:10.1002/ana.21127.CrossRefPubMed

Stroke therapy academic industry roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752–8.

Stroke therapy academic industry roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001;32(7):1598–606.

Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244–50. doi:10.1161/STROKEAHA.108.541128.CrossRefPubMedPubMedCentral

Saver JL, Jovin TG, Smith WS, Albers GW, Baron JC, Boltze J, et al. Stroke treatment academic industry roundtable: research priorities in the assessment of neurothrombectomy devices. Stroke. 2013;44:3596–601. doi:10.1161/STROKEAHA.113.002769.CrossRefPubMedPubMedCentral

Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007;30:433–9. doi:10.1016/j.tins.2007.06.009.CrossRefPubMed

10.

Llovera G, Hofmann K, Roth S, Salas-Perdomo A, Ferrer-Ferrer M, Perego C, et al. Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia. Sci Transl Med. 2015;7:299ra121. doi:10.1126/scitranslmed.aaa9853.CrossRefPubMed

11.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.

12.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29. doi:10.1056/NEJMoa0804656.CrossRefPubMed

13.

Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929–35. doi:10.1016/S0140-6736(14)60584-5.CrossRefPubMedPubMedCentral

14.

Albers GW, Goyal M, Jahan R, Bonafe A, Diener HC, Levy EI, et al. Relationships between imaging assessments and outcomes in Solitaire with the intention for thrombectomy as primary endovascular treatment for acute ischemic stroke. Stroke. 2015;46:2786–94. doi:10.1161/STROKEAHA.115.010710.CrossRefPubMed

15.

Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–107. doi:10.1056/NEJMoa1109842.CrossRefPubMed

16.

Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20. doi:10.1056/NEJMoa1411587.CrossRefPubMed

17.

Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–30. doi:10.1056/NEJMoa1414905.CrossRefPubMed

18.

Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015. doi:10.1056/NEJMoa1415061.PubMedCentral

19.

Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–18. doi:10.1056/NEJMoa1414792.CrossRefPubMed

20.

Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296–306. doi:10.1056/NEJMoa1503780.CrossRefPubMed

21.

Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893–903. doi:10.1056/NEJMoa1214300.CrossRefPubMedPubMedCentral

22.

Shen Q, Ren H, Cheng H, Fisher M, Duong TQ. Functional, perfusion and diffusion MRI of acute focal ischemic brain injury. J Cereb Blood Flow Metab. 2005;25:1265–79. doi:10.1038/sj.jcbfm.9600132.CrossRefPubMedPubMedCentral

23.

Fisher M. The ischemic penumbra: a new opportunity for neuroprotection. Cerebrovasc Dis. 2006;21 Suppl 2:64–70. doi:10.1159/000091705.CrossRefPubMed

24.

Saver JL. Time is brain--quantified. Stroke. 2006;37:263–6. doi:10.1161/01.STR.0000196957.55928.ab.CrossRefPubMed

25.

Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352–63. doi:10.1016/S0140-6736(12)60768-5.CrossRefPubMed

26.

Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914–23. doi:10.1056/NEJMoa1212793.CrossRefPubMedPubMedCentral

27.

Nagakane Y, Christensen S, Brekenfeld C, Ma H, Churilov L, Parsons MW, et al. EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke. 2011;42:59–64. doi:10.1161/STROKEAHA.110.580464.CrossRefPubMed

28.

Wheeler HM, Mlynash M, Inoue M, Tipirneni A, Liggins J, Zaharchuk G, et al. Early diffusion-weighted imaging and perfusion-weighted imaging lesion volumes forecast final infarct size in DEFUSE 2. Stroke. 2013;44:681–5. doi:10.1161/STROKEAHA.111.000135.CrossRefPubMedPubMedCentral

29.

Lansberg MG, Cereda CW, Mlynash M, Mishra NK, Inoue M, Kemp S, et al. Response to endovascular reperfusion is not time-dependent in patients with salvageable tissue. Neurology. 2015;85:708–14. doi:10.1212/WNL.0000000000001853.CrossRefPubMed

30.

Wintermark M, Flanders AE, Velthuis B, Meuli R, van Leeuwen M, Goldsher D, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke. 2006;37:979–85. doi:10.1161/01.STR.0000209238.61459.39.CrossRefPubMed

31.

Lin L, Bivard A, Levi CR, Parsons MW. Comparison of computed tomographic and magnetic resonance perfusion measurements in acute ischemic stroke: back-to-back quantitative analysis. Stroke. 2014;45:1727–32. doi:10.1161/STROKEAHA.114.005419.CrossRefPubMed

32.

Liebeskind DS, Jahan R, Nogueira RG, Jovin TG, Lutsep HL, Saver JL. Serial Alberta Stroke Program early CT score from baseline to 24 hours in Solitaire Flow Restoration with the Intention for Thrombectomy study: a novel surrogate end point for revascularization in acute stroke. Stroke. 2014;45:723–7. doi:10.1161/STROKEAHA.113.003914.CrossRefPubMedPubMedCentral

33.

Bratane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M. Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke. 2011;42:3265–70. doi:10.1161/STROKEAHA.111.618801.CrossRefPubMed

34.

Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M. Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model. J Cereb Blood Flow Metab. 2009;29:119–29. doi:10.1038/jcbfm.2008.104.CrossRefPubMed

35.

Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J, et al. Endovascular thrombectomy for acute ischemic stroke: a meta-analysis. JAMA. 2015;314:1832–43. doi:10.1001/jama.2015.13767.CrossRefPubMed

36.

Meyers PM, Schumacher HC, Connolly Jr ES, Heyer EJ, Gray WA, Higashida RT. Current status of endovascular stroke treatment. Circulation. 2011;123:2591–601. doi:10.1161/CIRCULATIONAHA.110.971564.CrossRefPubMedPubMedCentral

37.

Cloft HJ, Rabinstein A, Lanzino G, Kallmes DF. Intra-arterial stroke therapy: an assessment of demand and available work force. AJNR Am J Neuroradiol. 2009;30:453–8. doi:10.3174/ajnr.A1462.CrossRefPubMed

38.

Wardlaw JM, Dennis MS. Thrombectomy for acute ischemic stroke. JAMA. 2015;314:1803–5. doi:10.1001/jama.2015.14674.CrossRefPubMed

39.

Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924–8. doi:10.1161/STROKEAHA.107.490375.CrossRefPubMed

40.

Asplund K, Glader EL, Norrving B, Eriksson M. Effects of extending the time window of thrombolysis to 4.5 hours: observations in the Swedish stroke register (riks-stroke). Stroke. 2011;42:2492–7. doi:10.1161/STROKEAHA.111.618587.CrossRefPubMed

41.

Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011;42:1952–5. doi:10.1161/STROKEAHA.110.612358.CrossRefPubMedPubMedCentral

42.

O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467–77. doi:10.1002/ana.20741.CrossRefPubMed

43.

Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci. 2012;13:11753–72. doi:10.3390/ijms130911753.CrossRefPubMedPubMedCentral

44.

Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 2009;40:577–81. doi:10.1161/STROKEAHA.108.524330.CrossRefPubMed

45.

Tymianski M. Can molecular and cellular neuroprotection be translated into therapies for patients?: yes, but not the way we tried it before. Stroke. 2010;41:S87–90. doi:10.1161/STROKEAHA.110.595496.CrossRefPubMed

46.

Mehra M, Henninger N, Hirsch JA, Chueh J, Wakhloo AK, Gounis MJ. Preclinical acute ischemic stroke modeling. J Neurointerv Surg. 2012;4:307–13. doi:10.1136/neurintsurg-2011-010101.CrossRefPubMed

47.

Henninger N, Sicard KM, Schmidt KF, Bardutzky J, Fisher M. Comparison of ischemic lesion evolution in embolic versus mechanical middle cerebral artery occlusion in Sprague Dawley rats using diffusion and perfusion imaging. Stroke. 2006;37:1283–7. doi:10.1161/01.STR.0000217223.72193.98.CrossRefPubMed

48.

Manning NW, Campbell BC, Oxley TJ, Chapot R. Acute ischemic stroke: time, penumbra, and reperfusion. Stroke. 2014;45:640–4. doi:10.1161/STROKEAHA.113.003798.CrossRefPubMed

49.

Marosfoi MG, Korin N, Gounis MJ, Uzun O, Vedantham S, Langan ET, et al. Shear-activated nanoparticle aggregates combined with temporary endovascular bypass to treat large vessel occlusion. Stroke. 2015. doi:10.1161/STROKEAHA.115.011063.

50.

Henninger N, Bouley J, Nelligan JM, Sicard KM, Fisher M. Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume, and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 2007;27:1632–42. doi:10.1038/sj.jcbfm.9600463.CrossRefPubMed

51.

Kim HY, Singhal AB, Lo EH. Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. Ann Neurol. 2005;57:571–5. doi:10.1002/ana.20430.CrossRefPubMed

52.

Ip HL, Liebeskind DS. The future of ischemic stroke: flow from prehospital neuroprotection to definitive reperfusion. Interv Neurol. 2014;2:105–17. doi:10.1159/000357164.CrossRefPubMedPubMedCentral

53.

Jung JE, Kim GS, Chen H, Maier CM, Narasimhan P, Song YS, et al. Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for neuroprotection. Mol Neurobiol. 2010;41:172–9. doi:10.1007/s12035-010-8102-z.CrossRefPubMedPubMedCentral

54.

Bardutzky J, Meng X, Bouley J, Duong TQ, Ratan R, Fisher M. Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model. J Cereb Blood Flow Metab. 2005;25:968–77. doi:10.1038/sj.jcbfm.9600095.CrossRefPubMedPubMedCentral

55.

Henninger N, Fisher M. Stimulating circle of Willis nerve fibers preserves the diffusion-perfusion mismatch in experimental stroke. Stroke. 2007;38:2779–86. doi:10.1161/STROKEAHA.107.485581.CrossRefPubMed

56.

Bratane BT, Bouley J, Schneider A, Bastan B, Henninger N, Fisher M. Granulocyte-colony stimulating factor delays PWI/DWI mismatch evolution and reduces final infarct volume in permanent-suture and embolic focal cerebral ischemia models in the rat. Stroke. 2009;40:3102–6. doi:10.1161/STROKEAHA.109.553958.CrossRefPubMed

57.

Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372:528–36. doi:10.1056/NEJMoa1408827.CrossRefPubMedPubMedCentral

58.

Ebinger M, Winter B, Wendt M, Weber JE, Waldschmidt C, Rozanski M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA. 2014;311:1622–31. doi:10.1001/jama.2014.2850.CrossRefPubMed

59.

Audebert HJ, Saver JL, Starkman S, Lees KR, Endres M. Prehospital stroke care: new prospects for treatment and clinical research. Neurology. 2013;81:501–8. doi:10.1212/WNL.0b013e31829e0fdd.CrossRefPubMedPubMedCentral

60.

Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science. 2012;337:738–42. doi:10.1126/science.1217815.CrossRefPubMed

61.

van der Worp HB, Macleod MR, Bath PM, Demotes J, Durand-Zaleski I, Gebhardt B, et al. EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke. Int J Stroke. 2014;9:642–5. doi:10.1111/ijs.12294.CrossRefPubMed

62.

Horn CM, Sun CH, Nogueira RG, Patel VN, Krishnan A, Glenn BA, et al. Endovascular Reperfusion and Cooling in Cerebral Acute Ischemia (ReCCLAIM I). J Neurointerv Surg. 2014;6:91–5. doi:10.1136/neurintsurg-2013-010656.CrossRefPubMed

63.

van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain. 2007;130:3063–74. doi:10.1093/brain/awm083.CrossRefPubMed

64.

Donnino MW, Andersen LW, Berg KM, Reynolds JC, Nolan JP, Morley PT, et al. Temperature management after cardiac arrest: an advisory statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care. Perioper Resuscitation Circ. 2015. doi:10.1161/CIR.0000000000000313.

65.

Kuliha M, Roubec M, Jonszta T, Krajca J, Czerny D, Krajina A, et al. Safety and efficacy of endovascular sonolysis using the EkoSonic endovascular system in patients with acute stroke. AJNR Am J Neuroradiol. 2013;34:1401–6. doi:10.3174/ajnr.A3416.CrossRefPubMed

66.

Schellinger PD, Alexandrov AV, Barreto AD, Demchuk AM, Tsivgoulis G, Kohrmann M, et al. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial. Int J Stroke. 2015;10:1141–8. doi:10.1111/ijs.12536.CrossRefPubMed

67.

Fisher M, Saver JL. Future directions of acute ischaemic stroke therapy. Lancet Neurol. 2015;14:758–67. doi:10.1016/S1474-4422(15)00054-X.CrossRefPubMed

68.

dela Pena IC, Yoo A, Tajiri N, Acosta SA, Ji X, Kaneko Y, et al. Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis. J Cereb Blood Flow Metab. 2015;35:338–46. doi:10.1038/jcbfm.2014.208.CrossRef

69.

Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796–808. doi:10.1038/nm.2399.CrossRefPubMedPubMedCentral

70.

Sanderson TH, Reynolds CA, Kumar R, Przyklenk K, Huttemann M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol Neurobiol. 2013;47:9–23. doi:10.1007/s12035-012-8344-z.CrossRefPubMed

71.

Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke. 2004;35:2659–61. doi:10.1161/01.STR.0000144051.32131.09.CrossRefPubMed

72.

Leigh R, Jen SS, Hillis AE, Krakauer JW, Barker PB. Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator. Stroke. 2014;45:2030–5. doi:10.1161/STROKEAHA.114.005249.CrossRefPubMedPubMedCentral

73.

Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:1330–5.CrossRefPubMed

74.

Kent DM, Hinchey J, Price LL, Levine SR, Selker HP. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? Stroke. 2004;35:1141–6. doi:10.1161/01.STR.0000125712.02090.6e.CrossRefPubMed

75.

Lei C, Wu B, Liu M, Chen Y. Asymptomatic hemorrhagic transformation after acute ischemic stroke: is it clinically innocuous? J Stroke Cerebrovasc Dis. 2014;23:2767–72. doi:10.1016/j.jstrokecerebrovasdis.2014.06.024.CrossRefPubMed

76.

Park JH, Ko Y, Kim WJ, Jang MS, Yang MH, Han MK, et al. Is asymptomatic hemorrhagic transformation really innocuous? Neurology. 2012;78:421–6. doi:10.1212/WNL.0b013e318245d22c.CrossRefPubMed

77.

Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian Alteplase for Stroke Effectiveness Study registry. Stroke. 2007;38:75–9. doi:10.1161/01.STR.0000251644.76546.62.CrossRefPubMed

78.

Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015;132:1104–12. doi:10.1161/CIRCULATIONAHA.115.016371.CrossRefPubMed

79.

Schwamm LH, Holloway RG, Amarenco P, Audebert HJ, Bakas T, Chumbler NR, et al. A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2009;40:2616–34. doi:10.1161/STROKEAHA.109.192360.CrossRefPubMed

Titel: Extending the Time Window for Endovascular and Pharmacological Reperfusion
verfasst von: Nils Henninger
Marc Fisher
Publikationsdatum: 07.01.2016
Verlag: Springer US
Erschienen in: Translational Stroke Research / Ausgabe 4/2016
Print ISSN: 1868-4483
Elektronische ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-015-0444-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Strain-Related Differences in the Immune Response: Relevance to Human Stroke

Regulatory T Cells in Post-stroke Immune Homeostasis

Improving Reperfusion Therapies in the Era of Mechanical Thrombectomy

Phase III Preclinical Trials in Translational Stroke Research: Community Response on Framework and Guidelines

Impact of Comorbidities on Acute Injury and Recovery in Preclinical Stroke Research: Focus on Hypertension and Diabetes